Donepezil, galantamine and rivastigmine all ease Alzheimer symptoms the same basic way, and no one drug consistently beats the others on memory or daily function. The practical choice comes down to approved stage, dosing form, and side effects.
Cholinesterase inhibitors are drugs that block an enzyme called acetylcholinesterase. According to OpenStax, this leaves more acetylcholine available to surviving brain cells. They do not stop Alzheimer progression, only modestly and briefly slow decline.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What do these drugs actually do?
- Which drug matches which stage?
- Does one work better?
- What about side effects and daily dosing?
What do these drugs actually do?
They support communication between remaining nerve cells. According to OpenStax, they inhibit acetylcholinesterase and raise acetylcholine around surviving central cholinergic neurons. That can soften symptoms for a time.
Families should expect small, temporary help rather than recovery. According to OpenStax, the effect is a modest, short-term slowing of neuronal decline. Day-to-day change may mean slightly clearer attention or routine tasks, not restored memory.
Which drug matches which stage?
Approved use differs by stage and diagnosis. DailyMed lists donepezil for mild, moderate and severe Alzheimer dementia at 5 to 10 mg once daily in the DailyMed donepezil label. Its 23-mg dose is only for moderate-to-severe disease.
Galantamine covers a narrower Alzheimer range. DailyMed limits it to mild-to-moderate Alzheimer dementia in the DailyMed galantamine label. It comes as immediate- and extended-release tablets plus oral solution.
- Donepezil: mild, moderate and severe Alzheimer dementia; once-daily tablet.
- Galantamine: mild-to-moderate Alzheimer dementia only; tablet or liquid.
- Rivastigmine patch: mild, moderate and severe Alzheimer dementia plus mild-to-moderate Parkinson disease dementia, according to DailyMed in the DailyMed rivastigmine patch label.
Does one work better?
For mild-to-moderate Alzheimer disease, all three can help. Cochrane found each drug efficacious in its 2006 systematic review, described in the Cochrane evidence summary. The review found no consistent proof that one beats the others.
That finding shifts the decision toward fit and tolerance. Cognition and daily function look similar across drugs on average. Stage, other illness, drug form and side effects matter more.
What about side effects and daily dosing?
Stomach and appetite problems dominate. According to OpenStax and Cochrane, nausea, vomiting, diarrhea and appetite loss occur significantly more often than with placebo. For rivastigmine, the patch gives lower blood levels and less intense gut effects than capsules.
Dosing routine also differs in daily life. According to OpenStax, donepezil is once daily, with a 70-hour half-life and steady state in about 15 days. Galantamine has a 7-hour half-life, while rivastigmine offers capsule, solution or daily patch. Ask the prescriber which form the person can take reliably and what to do after a missed dose.
